China300584.CS2
Haichen Pharmaceutical Releases 2026 Interim Report with Net Profit of 32.065 Million Yuan
Haichen Pharmaceutical released its 2026 interim report on August 25, 2026. The company's total operating revenue was 364 million yuan, and net profit attributable to the parent company was 32.065 million yuan. Net cash flow from operating activities was negative 878,100 yuan, a decrease of 66.5158 million yuan compared with the same period last year, down 101.34 percent year on year. The company's latest asset-liability ratio was 26.09 percent, gross margin was 72.98 percent, down 12.90 percentage points from the same period last year, latest return on equity was 2.99 percent, and diluted earnings per share was 0.27 yuan. The company had 21,900 shareholders, and the top ten shareholders held 67.3996 million shares, accounting for 56.17 percent of total share capital.